Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy

Figure 2 Comparison of the granulocyte/lymphocyte ratio between patients who did (Lentinan+) and those who did not receive lentinan (Lentinan-) using the χ² test. A: Before therapy; B: At 3 mo after initiation of the S-1-based chemothrapy; C: At either 1 year after initiation of the S-1-based chemotherapy or 1 mo prior to death (cases in which the survival time was < 1 year after chemotherapy). P values of less than 0.05 were considered statistically significant. G/L: Granulocyte/lymphocyte.